Investments
11Portfolio Exits
4Funds
2About HealthCare Capital Partners
HealthCare Capital Partners is a venture capital firm based in Atlanta, Georgia formed in August 2003. The fund's primary focus is on making seed and early-stage investments in healthcare companies, including healthcare IT, medical technology, healthcare services, medical devices, diagnostics and life sciences. Our preference is to work with companies commercializing intellectual property affiliated with universities and other research institutions in the Southeast. They look for early-stage opportunities in rapidly growing companies with outstanding market opportunities. However, the fund is able to consider later-stage investments in companies where early investment liquidity appears likely. HCP likes to work closely with the entrepreneurs and scientists who are leading seed and early-stage companies.
Want to inform investors similar to HealthCare Capital Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest HealthCare Capital Partners News
May 16, 2023
Boundless Bio , a San Diego, CA-based clinical stage precision oncology company, raised $100M in Series C funding. The round was co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from Sectoral Asset Management, Piper Heartland Healthcare Capital and existing investors Fidelity Management & Research Company LLC, ARCH Venture Partners, Nextech Invest, Wellington Management, Vertex Ventures HC, Redmile Group, Surveyor Capital (a Citadel company), GT Healthcare Capital Partners, Alexandria Venture Investments, PFM Health Sciences, Logos Capital, and City Hill Ventures. In conjunction with the financing, Fabio Pucci, Ph.D., Senior Director of Venture Investments Health at Leaps by Bayer, will join the Boundless Bio Board of Directors. Led by CEO and President Zachary Hornby, Boundless Bio is a clinical stage, precision oncology company dedicated to the discovery and development of new drugs targeting a novel area of cancer biology, ecDNA, to deliver transformative therapies intended to improve and extend the lives of patients with oncogene amplified cancers. The company intends to use the funds to advance BBI-355, an ecDNA-directed therapy (ecDTx), through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncogene-amplified cancers, and a preclinical pipeline of differentiated ecDTx candidates and its proprietary ecDNA diagnostic clinical trial assay, ECHO (ecDNA Harboring Oncogenes), which is being developed in partnership with SOPHiA GENETICS. FinSMEs 16/05/2023
HealthCare Capital Partners Investments
11 Investments
HealthCare Capital Partners has made 11 investments. Their latest investment was in VelosBio as part of their Series B on July 7, 2020.
HealthCare Capital Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/8/2020 | Series B | VelosBio | $137M | Yes | Adage Capital Management, Arix Bioscience, Cormorant Asset Management, Decheng Capital, Farallon Capital Management, Foresite Capital, HealthCare Capital Partners, Janus Henderson Investors, Logos Capital, Matrix Capital Management, OrbiMed Advisors, Pappas Ventures, Sofinnova Ventures, Surveyor Capital, T. Rowe Price, Takeda Ventures, Venrock, Viking Global Investors, and Wellington Management | 3 |
2/21/2020 | Unattributed VC | eNeura Therapeutics | $0.51M | Yes | 1 | |
1/7/2019 | Series B | Exscientia | $26M | Yes | 2 | |
9/11/2008 | Series D | |||||
5/11/2007 | Seed VC |
Date | 7/8/2020 | 2/21/2020 | 1/7/2019 | 9/11/2008 | 5/11/2007 |
|---|---|---|---|---|---|
Round | Series B | Unattributed VC | Series B | Series D | Seed VC |
Company | VelosBio | eNeura Therapeutics | Exscientia | ||
Amount | $137M | $0.51M | $26M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | Adage Capital Management, Arix Bioscience, Cormorant Asset Management, Decheng Capital, Farallon Capital Management, Foresite Capital, HealthCare Capital Partners, Janus Henderson Investors, Logos Capital, Matrix Capital Management, OrbiMed Advisors, Pappas Ventures, Sofinnova Ventures, Surveyor Capital, T. Rowe Price, Takeda Ventures, Venrock, Viking Global Investors, and Wellington Management | ||||
Sources | 3 | 1 | 2 |
HealthCare Capital Partners Portfolio Exits
4 Portfolio Exits
HealthCare Capital Partners has 4 portfolio exits. Their latest portfolio exit was Exscientia on October 01, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/1/2021 | IPO | Public | 3 | ||
Date | 10/1/2021 | |||
|---|---|---|---|---|
Exit | IPO | |||
Companies | ||||
Valuation | ||||
Acquirer | Public | |||
Sources | 3 |
HealthCare Capital Partners Fund History
2 Fund Histories
HealthCare Capital Partners has 2 funds, including Health Care Capital.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
Health Care Capital | Early-Stage Venture Capital | Closed | 1 | ||
Healthcare II |
Closing Date | ||
|---|---|---|
Fund | Health Care Capital | Healthcare II |
Fund Type | Early-Stage Venture Capital | |
Status | Closed | |
Amount | ||
Sources | 1 |
HealthCare Capital Partners Team
4 Team Members
HealthCare Capital Partners has 4 team members, including current Founding Partner, Thomas Brooks.
Name | Work History | Title | Status |
|---|---|---|---|
Thomas Brooks | Founding Partner | Current | |
Name | Thomas Brooks | |||
|---|---|---|---|---|
Work History | ||||
Title | Founding Partner | |||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.